Physician profile
Thomas J Olaughlin
NPI 1306886916
$19,181.36
in general payments reported to CMS, 2019-2025
42 companies · $1,196 in 2025
The $1,196 reported for 2025 was more than what 76% of Pain Medicine (Physical Medicine & Rehabilitation) providers received nationally (typical 2025 total: $400).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,854 · 2020: $2,443 · 2021: $1,913 · 2022: $1,956 · 2023: $1,456 · 2024: $2,364 · 2025: $1,196.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,327 · Debt Forgiveness: $689.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,327.31 |
| Debt Forgiveness | $688.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biodelivery Sciences International, INC. | $8,318.42 | 2019-2021 | |
| Collegium Pharmaceutical, INC. | $1,923.92 | 2019-2025 | Xtampza, Belbuca, Jornay Pm |
| Abbvie INC. | $1,448.78 | 2021-2025 | |
| Indivior INC. | $835.19 | 2019-2025 | Sublocade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $771.05 | 2019-2025 | Relistor |
| Cadwell Industries, INC | $688.63 | 2024 | |
| Pfizer INC. | $428.69 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $417.46 | 2019-2025 | Rexulti |
| Uswm, LLC | $408.23 | 2021-2023 | Lucemyra, Zimhi |
| Allergan, INC. | $387.61 | 2020 | |
| Medtronic, INC. | $375.91 | 2022-2024 | Intellis Adaptivestim, Synchromedii |
| Biohaven Pharmaceuticals, INC. | $346.95 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $324.18 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $243.67 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $223.76 | 2019-2021 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Olaughlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.